Skip to main content
Contact Us
Subscribe
E-Edition
77°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
SAB Biotherapeutics, Inc. - Common Stock
(NQ:
SABS
)
1.840
-0.100 (-5.15%)
Streaming Delayed Price
Updated: 10:36 AM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about SAB Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
May 09, 2025
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
November 06, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO Reports Full Year 2024 Operating and Financial Results
March 31, 2025
SAB-142 Phase 1 trial positive topline data announced at KOL event
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
October 31, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO to Participate in Upcoming Investor Conferences
January 31, 2025
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
September 13, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
January 28, 2025
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
September 09, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
January 23, 2025
Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM EST
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
September 04, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
August 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
August 05, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAb Biotherapeutics Rebrands as SAB BIO
June 20, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
June 18, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB BIO Appoints Lucy To as Chief Financial Officer
July 31, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Departure of Chief Financial Officer
May 30, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
May 21, 2024
This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the US
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
May 20, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
May 06, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Provides SAB-142 Trial Update
April 16, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at INNODIA Annual Meeting
April 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
April 04, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
March 25, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
February 23, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Executive Leadership Change
February 02, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 23, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
January 02, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
November 29, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
November 20, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
